Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,

Slides:

Advertisements

Similar presentations

The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology by Pierre A. Buffet, Innocent Safeukui, Guillaume Deplaine,

Advertisements

GLUCOSE-6-PHOSPATE DEHYDROGENASE DEFICIENCY GENETICS PRESENTATION BY GROUP A2(MD2) WINDSOR UNIVERSITY SCHOOL OF MEDICINE. IVEREN,FOLA,FLOURISH, ALLISON,

Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

The influence of high-altitude living on body iron

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

How I treat autoimmune hemolytic anemias in adults

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Genetic sequence analysis of inherited bleeding diseases

Functional neutrophils from human ES cells

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

M.L. McMorrow, M. Aidoo, S.P. Kachur

Protease inhibitors potentiate chemotherapy-induced neutropenia

by Alexander Röth, Andreas Hüttmann, Russell P

by Ernest Beutler Blood Volume 98(9): November 1, 2001

Successful Treatment of Iron Overload by Phlebotomies in a Patient With Severe Congenital Dyserythropoietic Anemia Type II by W.K. Hofmann, J.P. Kaltwasser,

George Dailey, MD Mayo Clinic Proceedings

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

by Lori A. Styles, Anton J. Aarsman, Elliott P. Vichinsky, and Frans A

Blocking VWF platelet binding to treat TTP

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

by John J. Strouse, Megan E. Reller, David G

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea by Françoise Bernaudin, Cécile Arnaud,

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children by Patrick T. McGann, Anne M. Williams, Graham Ellis,

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

by Wendy Lim, Sara K. Vesely, and James N. George

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Volume 2(Supplement 1):39-41

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the.

How I treat autoimmune hemolytic anemia

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

by Lapo Alinari, and Kristie A. Blum

Initial treatment of CLL: integrating biology and functional status

Flowchart of modeling process for calculating anemia burden.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia by Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui,

Balancing bleeding in brain metastases

Cold agglutinin disease

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson, Nick Carter, Stephan Duparc, Zul Premji, Alfred B. Tiono, and Lucio Luzzatto Blood Volume 120(20): November 15, 2012 ©2012 by American Society of Hematology

Change in hemoglobin concentrations relative to values obtained at day 1 in children receiving a dapsone-containing combination or AL for the treatment of falciparum malaria. Allan Pamba et al. Blood 2012;120: ©2012 by American Society of Hematology

Hemolytic anemia in G6PD-deficient children with malaria receiving therapy with a dapsone- containing combination. Allan Pamba et al. Blood 2012;120: ©2012 by American Society of Hematology

Variability in hemoglobin levels in individual patients. Allan Pamba et al. Blood 2012;120: ©2012 by American Society of Hematology

Blood smears from a 3-year-old boy with acute malaria and G6PD deficiency treated with chlorproguanil-dapsone. Allan Pamba et al. Blood 2012;120: ©2012 by American Society of Hematology

The G6PD genotype was a major determinant of the severity of anemia in children given dapsone. Allan Pamba et al. Blood 2012;120: ©2012 by American Society of Hematology

Illustrative examples of the hematologic impact of dapsone in individual patients with falciparum malaria. Allan Pamba et al. Blood 2012;120: ©2012 by American Society of Hematology